Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Ad Campaign Challenges Sanofi Merger Bid

This article was originally published in The Pink Sheet Daily

Executive Summary

Aventis has launched an advertising campaign in European newspapers and magazines arguing against Sanofi-Synthelabo's $60 bil. hostile takeover bid

You may also be interested in...



Sanofi-Aventis/Altana's Asthma Therapy Alvesco Is "Approvable"

FDA says the review decision came directly from ODE II rather than the Division of Pulmonary & Allergy Drug Products. Aventis had touted Alvesco as one of six product launches that would drive organic growth during its attempts to fend off Sanofi's merger bid.

Sanofi-Aventis/Altana's Asthma Therapy Alvesco Is "Approvable"

FDA says the review decision came directly from ODE II rather than the Division of Pulmonary & Allergy Drug Products. Aventis had touted Alvesco as one of six product launches that would drive organic growth during its attempts to fend off Sanofi's merger bid.

GlaxoSmithKline Will Buy Arixtra, Fraxiparine In Event Of Sanofi/Aventis Merger

GSK would pay $541 mil. for the two anti-thrombotic agents and a manufacturing facility in France. The sale represents a preemptive divestiture on Sanofi's part; both products compete with Aventis' Lovenox.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel